BioSpace News Archive

Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, is pleased to announce two major additions to the team.

Bryn Pharma, LLC announced today that it has expanded its leadership team as the company further prepares for the market entry of UTULY™, an investigational self-administered form of epinephrine being studied for the treatment of type 1 allergic reactions, including anaphylaxis.

CYBRA Corporation, the New York-based developers of Edgefinity IoT® tracking software, announced the release of their latest case study highlighting the strategic value of an RFID-based tracking solution for the health and sciences industry.

PDS Biotechnology Corporation today announced that an abstract detailing immune response data from the VERSATILE-002 Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with unresectable, recurrent or metastatic human papillomavirus.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close on Tuesday, August 1, 2023.

Third Harmonic Bio, Inc. today announced its next-generation product candidate, THB335, a potent, highly selective oral small molecule KIT inhibitor with a meaningfully differentiated product profile as compared to the company’s first-generation product candidate THB001.

Blue Earth Diagnostics today announced that its optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent, POSLUMA® (flotufolastat F 18) injection.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.

Anbio, a leading provider of innovative diagnostic solutions, proudly presents its comprehensive RT-PCR solution that encompasses both pharmacogenomic and non-pharmacogenomic applications.

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.